Organigram Global Inc. (NASDAQ: OGI) announced a definitive agreement to acquire all issued and outstanding shares of Sanity Group GmbH, a leading German cannabis producer. The transaction values Sanity at €113.4 million, consisting of €80.0 million in cash and €33.4 million in Organigram shares. Sanity will also earn up to €113.8 million in earnout consideration based on its financial performance over the 12‑month period following closing.
The deal marks a strategic expansion into Europe, positioning Organigram as a global pure‑play cannabis producer with leadership in both the Canadian and European markets. The German medical cannabis market was valued at over €2 billion in 2025 and is projected to exceed €4.5 billion by 2028, making Sanity’s footprint a key entry point into the world’s second‑largest federally legal cannabis market. Organigram expects the transaction to close in the second quarter of 2026, subject to regulatory approvals and shareholder consent.
Organigram’s recent financial performance underscores the company’s readiness for this expansion. In its fiscal first quarter ending December 31, 2025, Organigram reported net revenue of $63.5 million, a 49% year‑over‑year increase, and a net income of $20 million. In contrast, the company posted a net loss of $38 million on $80.1 million of revenue in the fourth quarter of fiscal 2025, and a net loss of $5.4 million on $44.7 million of revenue in the fourth quarter of fiscal 2024. The acquisition will be financed through a combination of cash on hand, a new credit facility, and a C$65.2 million equity investment from British American Tobacco, which will provide the cash component of the deal. Organigram had previously invested €14 million in Sanity in June 2024, acquiring a minority stake and expanding its supply agreement.
Sanity Group has demonstrated rapid top‑line growth, with annual net revenue rising from €9 million in 2023 to €60 million in 2025, including €19 million in Q4 2025. The company operates Europe’s first two legal cannabis specialty stores in Switzerland and plans to expand into the UK and Poland. Sanity’s positive EBITDA in 2025 supports the earnout structure and signals strong profitability potential for the combined entity.
James Yamanaka, CEO of Organigram, said, "The proposed acquisition of Sanity Group marks a pivotal step in Organigram's global expansion strategy as a leader in the rapidly expanding cannabis industry." He added, "This transformational acquisition will bring together two market leaders, extend our commercial footprint into Europe, and strengthen our competitive edge in the world's largest federally legal cannabis markets." Paolo De Luca, Chief Strategy Officer at Organigram, said, "By combining our strengths as focused cannabis pure play companies, we will be well‑positioned to deliver meaningful value for our shareholders and accelerate growth in key European markets."
The transaction is subject to regulatory approvals in Canada, the United States, and Germany, as well as shareholder consent. Organigram expects to complete the deal in the second quarter of 2026 once all approvals are obtained.
The announcement was met with a positive market reaction, reflecting investor confidence in Organigram’s expanded European presence and the strategic fit of Sanity’s operations within the company’s global portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.